Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.
Evelo Biosciences has raised $25.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2023.
Evelo Biosciences's investors include Dementia Discovery Fund, Google Ventures, Flagship Pioneering, Alexandria Venture Investments, Horizon Technology Finance.
Evelo Biosciences is headquartered in Cambridge, United States.
Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.
Evelo Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Evelo Biosciences — Funding & Investors." VCBacked, July 10, 2023, https://www.vcbacked.co/company/evelo-biosciences. Accessed July 19, 2026.
VCBacked. (2023). Evelo Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/evelo-biosciences
{{cite web |title=Evelo Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/evelo-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated